[The high level resistance to carbapenems in Acinetobacter baumannii is a multifactorial problem].
Bou
G
G
Laboratory of Viral Immunology, Division of Infectious Diseases, Mayo Clinic, Rochester. USA. bou.german@mayo.edu
D000150:Acinetobacter / Q000187:drug effects* / Q000201:enzymology / Q000235:genetics; D000151:Acinetobacter Infections / Q000188:drug therapy* / Q000453:epidemiology; D001426:Bacterial Proteins; D015780:Carbapenems / Q000494:pharmacology*; D003428:Cross Infection / Q000188:drug therapy / Q000453:epidemiology / Q000382:microbiology; D004269:DNA, Bacterial / Q000235:genetics; D004196:Disease Outbreaks; D024901:Drug Resistance, Multiple, Bacterial / Q000235:genetics; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D000077731:Meropenem; D008826:Microbial Sensitivity Tests; D013030:Spain / Q000453:epidemiology; D013845:Thienamycins / Q000494:pharmacology; D018440:beta-Lactam Resistance / Q000235:genetics; D001618:beta-Lactamases / Q000235:genetics / Q000302:isolation & purification
D001426:Bacterial Proteins; D015780:Carbapenems; D004269:DNA, Bacterial; D013845:Thienamycins; D015378:Imipenem; D001618:beta-Lactamases; C410345:beta-lactamase OXA-24; C034413:beta-lactamase TEM-1; C063912:carbapenemase; D000077731:Meropenem